Brolucizumab
Treatment for Macular Degeneration
Typical Dosage: 6 mg intravitreal injection monthly for 3 doses, then every 8-12 weeks
Effectiveness
85%
Safety Score
35%
Clinical Trials
50
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
6 mg intravitreal injection monthly for 3 doses, then every 8-12 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$800
Side Effect Mgmt:$1,500
Total Annual:$14,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$90,000/QALY
QALYs Gained
0.75
Outcome-Based Costs
Cost per Responder
$15,888.89
Comparison vs Aflibercept
Cost Difference
+$1,250/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Brolucizumab Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+90%
Common Side Effects
Intraocular inflammation
+5%
Retinal vasculitis/occlusion
+3%
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Active Clinical Trials
2 active trials recruiting for Brolucizumab in Macular Degeneration
Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04985487RECRUITING
3K participants
OBSERVATIONAL
Daegu, South Korea +27 more
Started: Aug 18, 2021
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
NCT05959304ACTIVE NOT RECRUITINGPHASE4
63 participants
INTERVENTIONAL
Ahmedabad, India +7 more
Started: Dec 11, 2024
Completed Clinical Trials
12 completed trials for Brolucizumab in Macular Degeneration
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
NCT05111743COMPLETED
9.26K participants
OBSERVATIONAL
East Hanover, United States
Started: Jun 17, 2020
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
NCT05082415COMPLETED
9.46K participants
OBSERVATIONAL
East Hanover, United States
Started: Jun 3, 2020
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935COMPLETEDPHASE4
52 participants
INTERVENTIONAL
Regensburg, Germany +18 more
Started: Jul 13, 2021
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
NCT05037396COMPLETED
9.46K participants
OBSERVATIONAL
East Hanover, United States
Started: Mar 5, 2020
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
NCT04597632COMPLETEDPHASE3
248 participants
INTERVENTIONAL
Huntington Beach, United States +59 more
Started: Dec 16, 2020
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
NCT04774926COMPLETEDPHASE4
122 participants
INTERVENTIONAL
Ancona, Italy +19 more
Started: Oct 15, 2021
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
NCT04239027COMPLETEDPHASE3
210 participants
INTERVENTIONAL
Nice, France +39 more
Started: Jan 26, 2021
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
NCT04264819COMPLETEDPHASE3
295 participants
INTERVENTIONAL
Nice, France +50 more
Started: Dec 14, 2020
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
NCT05710471COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Jul 25, 2022
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
NCT03930641COMPLETEDPHASE3
34 participants
INTERVENTIONAL
Altamonte Springs, United States +2 more
Started: May 23, 2019
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
NCT04632056COMPLETED
329 participants
OBSERVATIONAL
Nagoya, Japan +66 more
Started: Nov 16, 2020
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05269966COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Asarwa, India +9 more
Started: Mar 9, 2022
Showing 20 of 50 total trials